Advertisement
Advertisement
U.S. markets close in 5 hours 10 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Chembio Diagnostics, Inc. (CEMI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.4200+0.0301 (+7.72%)
As of 10:44AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Engulfing Line (Bullish)

Engulfing Line (Bullish)

Previous Close0.3899
Open0.3727
Bid0.3780 x 1100
Ask0.3890 x 1300
Day's Range0.3705 - 0.4200
52 Week Range0.3400 - 2.5500
Volume153,263
Avg. Volume1,473,922
Market Cap12.694M
Beta (5Y Monthly)1.65
PE Ratio (TTM)N/A
EPS (TTM)-1.4260
Earnings DateNov 02, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CEMI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Chembio Diagnostics, Inc.
    OSUR: What does Argus have to say about OSUR?ORASURE TECHNOLOGIES INC has an Investment Rating of SELL; a target price of $3.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    8 days agoArgus Research
View more
  • GlobeNewswire

    Chembio Diagnostics Awarded $3.2 Million Contract from the CDC for Development and Clinical Validation of Dual-Path Platform Syphilis Screen & Confirm Assay

    HAUPPAUGE, N.Y., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced it was awarded a $3.2 million contract from the Centers for Disease Control and Prevention (CDC) for the development and clinical validation of a rapid point-of-care (POC) diagnostic test for syphilis. Chembio will undertake to develop a syphilis test and confirm assay based on its Dual Path Platform (D

  • Benzinga

    Is Monkeypox Outbreak Cooling? Health Officials Says Virus Transmission Has Slowed

    According to the World Health Organization, health officials are witnessing early signs that the new monkeypox case growth may be waning in Europe and the U.S. Public-health experts said they remain cautious about whether the outbreak has peaked as efforts continue to stretch limited vaccine supplies and protect vulnerable individuals. “If anything, we need to continue to strongly communicate and educate the public about this pathogen,” said Rodney Rohde, a public-health expert at Texas State Un

  • Benzinga

    Rapid Test For Monkeypox? NY-Based Chembio Diagnostics Thinks They Can Pull It Off

    Chembio Diagnostics Inc (NASDAQ: CEMI) is evaluating the potential to develop a monkeypox rapid point-of-care (POC) test. Chembio is exploring the technical requirements for test development leveraging its multiple technology platforms, DPP, SURE CHECK, and STAT PAK, along with funding partners and the broader market opportunity. "We are in dialogue with leading health organizations at the federal and state level to evaluate the need for a rapid test to detect and diagnose monkeypox. We are asse

Advertisement
Advertisement